[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pre-term\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pre-term":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,50,78,107,139,162,189,220,248],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100558026","admission-to-kangaroo-mother-care-kmc-ward-and-maternal-postpartum-depression-100558026",false,"NCT06545760","Admission to Kangaroo Mother Care (KMC) Ward and Maternal Postpartum Depression","Admission to the Kangaroo Mother Care Ward and Maternal Postpartum Depression: A Randomized Controlled Trial","KMC PPD","Inclusion Criteria:\n\n-AIM #1-2 and #5\n\nMothers to newborns who are:\n\n1\\) Birthweight between 1000-2000gm 2) Admitted to the Women and Neonates Hospital-University Teaching Hospital Neonatal Intensive Care Unit (WNH-UTH NICU) (\\>48hrs) 3) Stable preterm eligible for continuing kangaroo mother care (KMC) in the NICU or NICU discharge 4) 16+ years of age (Mother) 5) Residing within Lusaka Province with no intensions to relocate in the coming 18 months\n\n* AIM #3\n\n  1. Parents (mothers and fathers) whose newborn has been enrolled in the study\n  2. Trusted family member or friend of the mother whose newborns is enrolled into the study\n  3. 16+ years of age (mothers and fathers)\n  4. 18+ years of age (family members)\n* AIM # 4:\n\n  1. Fathers whose newborn has been enrolled into the study\n  2. 16+ years of age (father)\n\nExclusion Criteria:\n\n* AIM #1-2 and #5\n\n  1. Mothers who are on treatment for depression and\u002For anxiety\n  2. Mothers who did not consent\n  3. Underage mothers (16-17 years of age) whose parent(s) has not provided consent for their participation in the study\n* AIM #3\n\n  1\\) Family members of parents who do not consent to study participation\n* AIM # 4:\n\n  1. Fathers who are on treatment for depression and\u002For anxiety\n  2. Fathers who did not provide informed consent\n  3. Underage fathers (16-17 years of age) whose parent(s) has not provided consent for their participation in the study","ALL","1 Day","89 Years",{"count":21,"type":22},1908,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn if extended admission to the Kangaroo Mother Care (KMC) ward helps to prevent postpartum depression in mothers of low birthweight infants in a low-resource setting whose newborns were admitted to the neonatal intensive care unit (NICU) more than standard of care KMC. The main questions it aims to answer are:\n\n* Does longer KMC decrease the incidence of postpartum depression in mothers of low birthweight infants in a low-resource setting?\n* Does longer KMC improve neurodevelopmental outcomes of low birthweight infants at 6, 12, and 18 months in a low-resource setting?\n* What are the barriers to practicing KMC in low birthweight infants following hospital discharge in a low-resource setting?\n* What is the prevalence of paternal depression in a low resource setting?\n* Is it cost effective to admit preterm mother-infant dyads to the KMC ward following NICU discharge?\n\nResearchers will compare (extended admission to the KMC ward) to (standard of care KMC) to see if extended KMC decreases PPD in mothers of preterm infants in low-resource settings.\n\nParticipants (infants) will:\n\n* At time of discharge from the NICU, when clinically stable, spend either \\\u003C 2 days in the KMC ward with their mothers or spend longer in the KMC ward until discharge.\n* Return to clinic at routine follow-up visits (at 2 weeks and at 6-8 weeks) where mothers will be screened for postpartum depression and fathers will be screened for depression.\n* Return to clinic for neurodevelopmental screening at 6, 12, and 18 months where mothers will be screened for postpartum depression and perceived social support and fathers will be screened for depression.",[28,29,30,31,32],"Low Birth Weight","Kangaroo Mother Care","Postpartum Depression","Neurodevelopmental Outcome","Pre-Term",[34,29,35,36],"Low resource setting","Paternal depression","Cost-effectiveness","RECRUITING","2026-06-18",{"date":40,"type":41},"2026-06-22","ACTUAL",{"date":43,"type":41},"2024-12-01",{"date":45,"type":22},"2027-09-30",{"name":47,"class":48},"University of Alabama at Birmingham","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":49},"100613090","phase-2-improving-preterm-kidney-outcomes-with-caffeine-100613090","NCT07262060","Improving Preterm Kidney Outcomes With Caffeine","Optimizing Caffeine Therapy for Hypoxia in Preterm Neonates: A Randomized Trial Assessing Efficacy, Acute Kidney and Brain Injury, Safety, and Pharmacokinetics","Inclusion Criteria:\n\n* Gestational age at birth between 23 0\u002F7 and 29 6\u002F7 weeks.\n* Able to have near-infrared spectroscopy (NIRS) monitoring of cerebral and kidney oxygenation.\n* Able to receive IV medications.\n* Indwelling umbilical arterial catheter (UAC), umbilical venous catheter (UVC), peripheral arterial line (PAL), or peripherally inserted central catheter (PICC) already in place that can draw blood.\n* Receiving caffeine at the time of enrollment\n* Have a birth parent who is at least 18 years old and have a parent or guardian who is able to provide parental permission in English or Spanish\n\nExclusion Criteria:\n\n* Known or suspected major congenital anomaly of the brain, heart, lungs or kidney (excluding UTD A1 pyelectasis).\n* Known or suspected chromosomal or genetic anomaly.\n* Not suitable for study participation due to other reasons at the discretion of the investigators.","12 Hours","96 Hours",{"count":60,"type":22},114,[62],"PHASE2","This study is being done to see if additional caffeine citrate (20 milligrams per kilogram IV bolus) helps babies with low kidney oxygenation already being treated with caffeine citrate (20 milligrams per kilogram IV bolus on day of life (DOL) 1 followed by 8 milligrams per kilogram daily maintenance). The investigators hypothesize that additional caffeine will improve kidney oxygen levels, while not causing any brain injury, and may reduce rates of acute kidney injury compared to placebo. This study will take place in preterm babies born less than 30 weeks gestational age, with the intervention occurring between greater than 48 hours of age until DOL 14 and outcomes tracked until neonatal intensive care unit (NICU) discharge.",[65,32],"Kidney Injury",[67,68],"caffeine","acute kidney injury","2026-06-02",{"date":71,"type":41},"2026-06-04",{"date":73,"type":41},"2026-05-28",{"date":75,"type":22},"2030-09",{"name":77,"class":48},"University of Wisconsin, Madison",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":49},"100609551","predictive-value-of-lung-ultrasound-for-respiratory-decompensation-in-late-preterm-neonates-100609551","NCT07216053","Predictive Value of Lung Ultrasound for Respiratory Decompensation in Late Preterm Neonates","Inclusion Criteria:\n\n* Inborn infants born between 34w0d and 36w6d gestational age\n* In RA or 1 Litre per minute 1LPM NC (room air (RA) or nasal cannula (NC))\n* Admitted to NICU or Well Baby Nursery (WBN)\n\nExclusion Criteria:\n\n* Patients born \\\u003C34 weeks or \\>36w6d\n* Major genetic anomaly or syndromic condition\n* Cardiac or pulmonary structural defects\n* Cord pH \\\u003C7.0 or 5 minute APGAR 5 or less\n* Suspected fetal hemorrhage or other source of significant anemia at birth","34 Weeks","36 Weeks",{"count":87,"type":22},300,"OBSERVATIONAL","Respiratory morbidity presents a significant clinical challenge in the neonatal period, and an individual patient's clinical course is often difficult to predict. This is especially true for late-preterm infants, who share some of the same risks of premature babies in terms or respiratory morbidity, but whose births may not always be attended by a neonatologist, or who may be born at hospitals with lower level Neonatal Intensive Care Units (NICUs) and require transfer if they decompensate.\n\nWith this study, the aim is to 1) determine the efficacy of early point of care lung ultrasound (LUS) to predict respiratory decompensation in the first 48 hours of life in late preterm infants and 2) to compare the performance of three lung ultrasound scoring systems, 3 type-of-lung, high risk pattern and total LUS scoring systems.",[32,91,92],"Respiratory Distress of Newborn","Premature",[94,95,96,97],"Lung Ultrasound","Respiratory Decompensation","Late Preterm Neonates","respiratory distress","2026-05-20",{"date":100,"type":41},"2026-05-22",{"date":102,"type":41},"2025-11-06",{"date":104,"type":22},"2027-11",{"name":106,"class":48},"Hackensack Meridian Health",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":118,"conditions":119,"keywords":124,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":49},"100578123","motor-voice-assessment-in-infants-mami-100578123","NCT06807203","Motor-voice Assessment in Infants (MAMI)","Spontaneous Motor-voice Assessment in Infants Using Video and Audio Recordings.","MAMI","Inclusion Criteria:\n\n* gestational age of 24 0\u002F7 - 41 6\u002F7,\n* admitted to the NICU,\n* medically stable by 40 weeks of gestation (including off ventilator support),\n* born to mothers 18 - 43 years old at the time of birth,\n* one parent fluent in English.\n\nExclusion Criteria:\n\n* diagnosis of a genetic syndrome (e.g. Trisomy 21),\n* musculoskeletal deformity,\n* failed hearing screen.","10 Days",{"count":117,"type":22},46,"The goal of this observational study is to discover features of normal and disordered motor-voice profiles that are biobehavioral markers of physical disability in infants.. The main questions it aims to answer are:\n\nIdentify voice factors among infants with newborn-detectable risk. Identify association between individual characteristics (Gestational age at birth, global function, motor-function) and voice factors.\n\nExamine unique features of voice production that are present in infants with high-risk for Cerebral Palsy (CP).\n\nParticipants will be asked to upload a 3-minute videos of their child at term-age, 3.5-, and 9-months of age.\n\nAt the 3.5-month and 9-month time point parents can choose to attend an optional in-person assessment with their child.",[120,32,121,122,123],"Cerebral Palsy Infantile","Motor Delay","Neurodevelopmental Disorders","Autism Spectrum Disorder",[125,126,127,128,129],"Digital health,","Motor assessment,","voice assessment,","cognition","neurodevelopment,","2026-03-24",{"date":132,"type":41},"2026-03-27",{"date":134,"type":41},"2025-10-22",{"date":136,"type":22},"2030-01-28",{"name":138,"class":48},"Ohio State University",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":147,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":49},"100556514","cerebral-oxygen-saturation-monitoring-during-optimum-cord-management-in-preterm-infants-100556514","NCT06526091","Cerebral Oxygen Saturation Monitoring During Optimum Cord Management in Preterm Infants","Cerebral Oxygen Saturation Monitoring During Optimum Cord Management in Preterm (COSMIC Pilot Study)","COSMIC","Inclusion Criteria:\n\n* All babies eligible for optimum cord management born before 34 completed weeks gestational age\n* Parental consent\n\nExclusion Criteria:\n\n* Multiple pregnancies\n* Infants for whom resuscitation at birth is not appropriate\n* Antenatal or immediate postnatal diagnosis of severe congenital anomaly\n* Infants with complex congenital cardiac disease","1 Minute","24 Hours",{"count":150,"type":22},40,"This study will assess the feasibilty measuring cerebral oxygen saturations using a Near Infrared Spectroscopy (NIRS) monitor immediately after delivery of preterm infants. The investigators aim to evaluate the effects of optimum cord management on cerebral oxygenation in this cohort",[32],"2024-07-26",{"date":155,"type":41},"2024-07-29",{"date":157,"type":41},"2023-02-15",{"date":159,"type":22},"2024-10-01",{"name":161,"class":48},"Imperial College Healthcare NHS Trust",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":169,"sex":17,"minAge":170,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":23,"phases":174,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":49},"100553446","preemie-milk-analyser-validation-study-100553446","NCT06486194","Preemie Milk Analyser Validation Study","Analytical Validation and Clinical Testing of the Preemie System for Analysis and Calculation of Targeted Fortification of Mother's Breast Milk for Preterm Infants","Inclusion criteria Phase 1A For University Hospital Southampton (UHS) milk bank donors\n\n* Approved as a donor for the UHS milk bank through the usual process\n* Be providing milk to UHS donor milk bank For mothers of infant inpatients\n* Have an infant who is currently an inpatient in the neonatal unit, paediatric wards, paediatric cardiac ward, or paediatric intensive care unit\n* Be providing breastmilk for their preterm or term born infant\n* Have sufficient breast milk available such that providing 120ml breast milk for the study does not impact on the needs of their infant.\n\nInclusion criteria Phase 1B\n\n* Approved as a donor for the UHS milk bank through the usual process\n* Be providing milk to UHS donor milk bank\n\nExclusion criteria Phase 1A and 1B For mothers of infant inpatients\n\n\\- Mothers whose infants are inpatients and where there is a concern about adequacy of maternal milk supply to feed their infant\n\nInclusion Criteria Phase 2\n\n* Birth weight ≥1kg and \\\u003C1.8 kg (so meet the ESPGHAN criteria for breast milk fortification)\n* Be taking fully fortified enteral breast milk feeds (≥150 ml\u002Fkg\u002Fday of mothers or donor breast milk containing breast milk fortifier as per the manufacturer's instructions)\n* Tolerating fully fortified breast milk feeds≥150 ml\u002Fkg\u002Fday for 48 hours\n* No longer on parenteral nutrition.\n\nExclusion Criteria Phase 2\n\n* Infants where there is a concern about mother's supply of breast milk being insufficient to meet demands (where donor milk is not being used to make up any shortfall);\n* Known congenital metabolic disorder;\n* Infant formula fed;\n* Bilateral grade III or IV intraventricular haemorrhage;\n* Any infant who has had gastrointestinal tract surgery;\n* Refusal of consent;\n* Refusal for the use of breast milk fortifier\n* Birthweight \\\u003C1 kg",true,"0 Days","50 Years",{"count":173,"type":22},180,[25],"This study aims to test and validate the Preemie Ecosystem- a new device and associated software package for measuring the nutrient (fat, protein and carbohydrate) content of the breast milk of the mothers of premature babies. This is potentially useful, as premature babies have higher nutritional requirements than babies born at term near their due date. At the moment, a nutritional supplement called breast milk fortifier is added to breast milk in standard amounts to improve its nutritional content and help premature babies grow. However, we know that each mother's breast milk is different, and varies from day to day, so each mother's milk may require more or less of such supplements in order to meet European recommendations for the nutrient intake.\n\nThe aim of this study is to first test and validate the accuracy of the Preemie device for measuring the nutritional content of mother's breast milk, using milk donated to the local donor milk bank and from mothers of babies currently on the neonatal unit. Next, once this is complete, the aim is to demonstrate it is feasible to use the Preemie device to enable fortification of mother's milk on an individualised basis for a small group of premature babies. The growth and nutrient intakes of these babies will be compared to another group who are cared for using the standard fortification approach.\n\nThe results of this study will be used to gain \"Conformité Européenne\" (CE) certification of the Preemie device and software.",[32,177,178],"Breast Milk Expression","Nutrition Disorder, Infant","NOT_YET_RECRUITING","2024-06-26",{"date":182,"type":41},"2024-07-03",{"date":184,"type":22},"2024-07-01",{"date":186,"type":22},"2026-07-01",{"name":188,"class":48},"University Hospital Southampton NHS Foundation Trust",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":169,"sex":196,"minAge":197,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":219},"100547951","multicenter-prospective-cohort-study-of-twin-maternal-child-dyads-in-china-100547951","NCT06414655","Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China","ChiTwiMC","Inclusion Criteria:\n\n* Twin pregnancies\n* Female aged between 18-45 years\n* Gestational age is less than 14 weeks\n* Planning to receive prenatal healthcare and delivery service at the study hospital\n* Signing informed concent and willing to participate\n\nExclusion Criteria:\n\n* Women with mental disorders or serious maternal illness that is not eligible to participate\n* Inability to provide informed consent\n* Pregnant women not registered in our hospital","FEMALE","18 Years","45 Years",{"count":200,"type":22},2000,"Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China (ChiTwiMC) is supported by National Key Research and Development Program of China - Reproductive Health and Women's and Children's Health Protection Project. This project is funded by the Ministry of Science and Technology of China under grant number 2023YFC2705900. The ChiTwiMC cohort is led by Professor Wei Yuan from the Department of Gynecology and Obstetrics at Peking University Third Hospital.",[203,204,32,205,206,207,208,209],"Twin Pregnancy, Antepartum Condition or Complication","Twin to Twin Transfusion as Antepartum Condition","Pre-Eclampsia","Twin Monochorionic Diamniotic Placenta","Twin Dichorionic Diamniotic Placenta","High Risk Pregnancy","Twin Placenta","2024-05-09",{"date":212,"type":41},"2024-05-16",{"date":214,"type":41},"2024-03-01",{"date":216,"type":22},"2026-11-30",{"name":218,"class":48},"Peking University Third Hospital",11,{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":169,"sex":196,"minAge":197,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":229,"conditions":230,"keywords":233,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":4},"100453709","study-of-pregnancy-pathologies-associated-with-placental-abnormalities-100453709","NCT05188066","Study of Pregnancy Pathologies Associated With Placental Abnormalities","Inclusion Criteria:\n\nAdult women\n\n* Admitted to the CHUGA for a birth or an abortion.\n* Pregnant women consenting to the collection of their fetal placenta membranes, during premature deliveries or at term of pregnancy OR Women performing an abortion consenting to the collection of their abortion products.\n* Having signed a consent\n* Affiliated with social security\n\nExclusion Criteria:\n\n* Placental sample or abortion product unavailable (not collected or necessary for treatment).\n* Patient with known positive HIV or Hepatitis B or Hepatitis C serology or at risk according to the infectious safety criteria applied by the EFS.\n* hemoglobin \\\u003C7d \u002F dL or hemoglobin \\\u003C10g \u002F dL if she suffers from a cardio-respiratory pathology).\n* Patient protected by law (minor, hospitalized under duress, subject to a legal protection measure by guardianship or curatorship, deprived of liberty by judicial or administrative decision)","52 Years",{"count":228,"type":22},800,"Pregnancy pathologies can occur from implantation until childbirth. The investigators are interested in the development mechanisms of these pathologies and aim to develop therapies to treat them.\n\nThe investigators need to collect samples, especially placental samples, following abortions and term and premature deliveries. Abortions will allow investigators to have non-pathological placental material up to 13 weeks. This material will serve as a reference for the understanding of the histological changes that occur in normal placentas collected at term of pregnancy. The latter will, in turn, be compared with the placentas collected during premature deliveries. Also, the abortion product will be cultivated in an environment mimicking the pathology of pre-eclampsia. This study will allow investigators to advance their understanding of the pathophysiological mechanisms of the placenta. The investigators are internationally recognized for their research on these pathologies.",[231,32,232],"Pre-eclampsia","Fetal Growth Retardation",[234,235,236,237,238],"pre-eclampsia","fetal growth retardation","placenta histology","vascularization","trophoblast proliferation","2022-01-07",{"date":241,"type":41},"2022-01-12",{"date":243,"type":22},"2022-01-06",{"date":245,"type":22},"2030-01-31",{"name":247,"class":48},"University Hospital, Grenoble",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":255,"enrollmentInfo":256,"targetDuration":4,"studyType":23,"phases":257,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":49},"100359905","phase-3-citicoline-as-neuroprotector-in-preterm-100359905","NCT03966170","Citicoline as Neuroprotector in Preterm","Efficacy of Citicoline as Neuroprotector in Preterm; A Randomized Controlled Trial","Inclusion Criteria:\n\n* Preterm on CPAP or ventilator\n\nExclusion Criteria:\n\n* Multiple congenital anomalies","1 Month",{"count":150,"type":22},[258],"PHASE3","Citicoline as neuroprotector in preterm",[32],"2019-05-24",{"date":263,"type":41},"2019-05-29",{"date":265,"type":41},"2019-05-01",{"date":267,"type":22},"2028-12",{"name":269,"class":48},"Sherief Abd-Elsalam"]